# Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

> **NCT04734990** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia-0
- Chronic Myelomonocytic Leukemia-1
- Chronic Myelomonocytic Leukemia-2
- Myelodysplastic Syndrome
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Seclidemstat

## Key facts

- **NCT ID:** NCT04734990
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-07
- **Primary completion:** 2027-09-11
- **Final completion:** 2027-09-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04734990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04734990, "Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04734990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*